Australia’s medical device market is in a strong growth phase, powered by an ageing population, rising chronic disease, a robust hospital sector, and an increasingly sophisticated MedTech ecosystem. Growth is also supported by a stable regulatory framework under the Therapeutic Goods Administration (TGA) and targeted government and investor support for medical technologies and pharmaceuticals.
1. Market size and growth outlook
Analysts broadly agree that the Australian medical device market will expand steadily through 2030 and beyond.
- A 2025 market report, Australia Medical Devices Market Outlook to 2030, notes that the sector is set for “steady expansion” driven by an ageing population, chronic disease, hospital capital investment, and strong adoption of home‑based and ambulatory care.
- Data Bridge Market Research projects that the Australia medical devices market will reach about USD 421.9 billion by 2032, growing at a CAGR of 9.4% from 2025–2032.
- A separate industry note in Medical Product Outsourcing, “Australian Medical Devices Market to Reach $14 Billion in 2030”, forecasts around AUD 14 billion by 2030, implying roughly 5% annual growth over seven years.
Statista’s Medical Devices – Australia market forecast similarly describes the market as “experiencing growth and development due to customer preferences for innovative and technologically advanced products,” with robust per‑capita spending compared with many Asia–Pacific peers.
Even niche segments are expanding fast. For example, Grand View Research reports that the Australia medical device contract manufacturing market generated USD 344.6 million in 2024 and is expected to reach USD 751.7 million by 2030, a CAGR of 14.3% from 2025–2030. Its related reprocessed medical devices market is also projected to grow strongly.
2. Demand drivers: demographics, chronic disease and care models
Several structural factors underpin medical device market growth in Australia.
Ageing population and chronic disease
TraceData Research notes that the ageing population and rising burden of chronic conditions (cardiovascular, oncology, respiratory, diabetes) are central drivers of device utilisation across imaging, implantables, surgical tools and diagnostics. As people live longer, demand rises for joint replacements, cardiac implants, diagnostic imaging, and home‑based monitoring.
A MedTech recruitment outlook, “MedTech Industry Growth in Australia: 2025 Outlook”, highlights similar themes: Australians’ increasing life expectancy and chronic disease incidence are fuelling demand for medical devices and diagnostics, both domestically and in export markets.
Hospital investment and procedure volumes
TraceData’s outlook notes that public and private hospital networks are modernising imaging and theatre ecosystems and sustaining high procedure volumes, especially for minimally invasive and ambulatory surgery. This translates into continuous demand for devices across:
- Surgical technologies
- Diagnostic imaging equipment
- Interventional cardiology and oncology devices
- Infection‑prevention and patient‑monitoring systems
Nexdigm’s Australia Medical Supplies Market Outlook to 2030 values the broader medical supplies market at USD 7.4 billion in 2024, reflecting strong procurement by hospitals and clinics.
Shift to home‑based and ambulatory care
The TraceData report emphasises the shift towards home‑based and ambulatory care, which is boosting demand for portable monitoring, connected devices and diagnostics suited to telehealth and virtual care pathways. Infrastructure for telehealth and home‑based services is relatively well‑developed in Australia, making clinicians and patients more receptive to digital and portable solutions.
3. Segment trends: portable, reprocessed and contract manufacturing
Within the broader market, some segments are growing faster than others.
Portable and connected devices
TraceData Research notes that portable medical devices dominate the Australian market by value. Growth is driven by:
- Increasing demand for point‑of‑care monitoring in chronic respiratory, cardiac and diabetes management.
- Rising use of at‑home diagnostics and remote monitoring.
- Expanding telehealth and home‑based care pathways supported by reimbursement.
- Post‑pandemic normalisation of wearable and portable tech adoption.
The report highlights that established players continue to innovate with compact, user‑friendly, connected devices, while digital health/Software as a Medical Device (SaMD) is emerging rapidly, though still maturing within the health system.
Reprocessed devices and sustainability
The Australia Reprocessed Medical Devices Market is another growth area, with MarkNtel Advisors estimating market size at USD 319 million in 2024 and projecting it to reach USD 506 million by 2030. Demand is fuelled by cost‑containment efforts and sustainability goals in hospitals, which are increasingly open to high‑quality reprocessed devices for appropriate indications.
Contract manufacturing and local production
Grand View Research’s Australia medical device contract manufacturing study projects a 14.3% CAGR to 2030, driven by OEMs outsourcing production to optimise costs and leverage specialised capabilities. TraceData notes that local manufacturing incentives and supply‑chain resilience programs are encouraging technology transfer and local assembly, boosting domestic contract manufacturing activity.
4. Industry structure and economic impact
Australia’s MedTech sector is economically significant and increasingly export‑oriented.
The Medical Technology Association of Australia (MTAA) provides an economic snapshot in a report hosted by Jobs and Skills Australia. It finds that:
- MedTech gross revenues in Australia totalled AUD 11.4 billion in 2021/22, reflecting a compound annual growth rate of 6.2% over the previous two years.
- The sector’s total contribution to GDP was about AUD 5.4 billion, comprising AUD 4.1 billion in direct GDP and AUD 1.4 billion in indirect GDP via supply chains.
- This implies a 5.9% nominal CAGR in GDP contribution over two years.
The same report notes that Australia’s MedTech industry supports over 51,000 jobs (direct and indirect), spanning manufacturing, R&D, clinical trials, distribution, and supporting services.
MTPConnect—Australia’s growth centre for Medical Technologies, Biotechnologies and Pharmaceuticals—reiterates this momentum in its 2024 Annual Report, highlighting continued support for life science innovators, commercialisation programs, and sector‑wide revenue growth. MedTech is an explicit priority industry for economic development and advanced manufacturing.
5. Regulatory environment: TGA, ARTG and market access
A stable, predictable regulatory environment is a key enabler of market growth.
TGA framework
The Therapeutic Goods Administration (TGA) oversees the supply of medical devices and in vitro diagnostics (IVDs) in Australia. Its role is to ensure device safety and effectiveness before and after market entry, as summarised in Understanding TGA Regulations for Medical Devices in Australia.
Key regulatory elements include:
- Risk‑based classification – medical devices are classified as Class I, IIa, IIb, III, and Active Implantable Medical Devices (AIMDs), while IVDs have four risk classes.
- Conformity assessment – manufacturers must demonstrate compliance with Essential Principles for safety, quality, design and performance, typically under an ISO 13485‑aligned QMS.
- Inclusion in the ARTG – devices must be included in the Australian Register of Therapeutic Goods (ARTG) to be legally supplied.
- Post‑market monitoring – TGA assesses adverse event reports, inspects manufacturers, and can impose reporting or corrective action requirements to ensure ongoing safety.
The TGA’s official overview of medical devices and IVD regulation details these processes and notes that low‑risk Class I devices may be self‑declared, while higher‑risk classes require more extensive evidence and third‑party certification.
Routes to market: abridged vs full assessment
For foreign manufacturers, Australia offers multiple regulatory routes. The Qserve Group’s guide, “Australia TGA Medical Device Regulations”, explains that there are two primary pathways:
- An abridged route, which provides faster assessment for devices that already have recognised approvals (such as CE mark, FDA approval, MDSAP certification or approvals from Singapore/Malaysia/India).
- A full TGA Conformity Assessment Route, involving comprehensive review of technical documentation and QMS when overseas approvals cannot be leveraged.
Elendi Labs’ overview of medical devices and IVD regulation in Australia further outlines classification rules, conformity assessment, ARTG inclusion and post‑market obligations, offering a concise reference for MedTech companies planning entry or expansion.
6. Innovation, talent and ecosystem strengths
Australia’s medical device market growth is also an innovation story.
The MedTech Industry Growth 2025 Outlook notes that the sector is being reshaped by advances in biotechnology, digital health, artificial intelligence and telehealth, enabling next‑generation diagnostic tools, wearables, and connected platforms. Integration of AI and machine learning is improving product performance and creating new service‑based business models.
TraceData’s market outlook emphasises the strength of clinician networks, university–industry collaborations and clinical trial ecosystems in hubs like Melbourne and Sydney. Melbourne hosts a strong medtech manufacturing cluster, while Sydney offers access to contract research and testing services, making both cities epicentres of market activity and adoption.
MTPConnect’s 2024 Annual Report underscores the role of government‑backed programs in commercialisation, such as BioMedTech Horizons and the Targeted Translation Research Accelerator, which help early‑stage devices move from concept to clinic. This support, combined with world‑class research institutions and a respected regulatory regime, creates a favourable environment for MedTech start‑ups and scale‑ups.
7. Strategic implications for companies
For device manufacturers, investors and service providers, several themes stand out:
- Focus on high‑growth segments – portable and connected devices, minimally invasive technologies, and home‑based monitoring are standout growth areas, backed by demographic trends and care models.
- Align with TGA and reimbursement – success depends on navigating TGA requirements and aligning with Australian reimbursement frameworks (MBS and Prostheses List), which reward clinically proven, cost‑effective innovations.
- Leverage contract manufacturing and local incentives – using local partners and incentive programs can improve supply‑chain resilience and support local assembly, especially for high‑value devices.
- Build evidence and clinician advocacy – registry‑driven evidence, clinician KOL networks, and robust post‑market data are crucial for adoption in a clinically conservative environment.
- Tap into Asia–Pacific exports – MedTech industry analyses highlight growing demand in neighbouring Asian markets, positioning Australian device companies well for regional expansion.
For deeper data and context, you can point readers to external resources such as TraceData’s Australia Medical Devices Market Outlook, Data Bridge’s long‑range forecasts, MTAA’s economic snapshot, and the TGA’s regulatory overviews, then connect those to your own internal content on Australian MedTech strategy, regulatory readiness, or go‑to‑market planning.